amphastar.com (AMPH): Net earnings per share growth forecast for next year
Expectations for changes in net earnings per share confirm high margins driven by in-house raw material production for Amphastar Pharmaceuticals (AMPH). The value 4.90 reflects the latest metric reading. The B2B model for complex injectables creates a formidable barrier to entry for competitors due to FDA standards. Stability is ensured by a mix of proprietary drugs and generics that Amphastar Pharmaceuticals (AMPH) supplies to pharmacy chains and clinics.
Amphastar Pharmaceuticals, Inc. (AMPH) - metric breakdowns and financial figures
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- company book value details:
- company total debt and liquidity indicators:
Debt to Equity Amphastar Pharmaceuticals|AMPH - Long-Term Liabilities to Equity|Short-Term Debt to Capital Amphastar|AMPH - Aggregate Debt Obligations|Debts to Book Capitalization Amphastar Pharmaceuticals, Inc.|AMPH - Company Long-Term Debts|Company Short-Term Debt Amphastar Pharmaceuticals|Quick Liquidity Indicator amphastar.com
- earnings and valuation multiples information:
AMPH - Profit After Payment of Taxes|Projected Future Earnings Amphastar Pharmaceuticals|AMPH - P/E Multiple|Future Price to Earnings Amphastar Pharmaceuticals, Inc.|AMPH - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Amphastar|AMPH - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Amphastar Pharmaceuticals|AMPH - Earnings per one share for the last 12 months|Quarterly EPS earnings growth amphastar.com|AMPH - Earnings per share increase in current year|Earnings growth forecast for next year Amphastar Pharmaceuticals
- revenue and sales proceeds data:
Fundamental company valuation:Amphastar Corp, AMPH
This indicator captures the trend of expert earnings per share (EPS) expectations, where peaks reflect maximum market optimism and the risk of a correction should a divergence from reality occur. By analyzing the modeled EPS growth for the next fiscal year, investors assess the efficiency of the Amphastar Pharmaceuticals (AMPH) business model, considering the impact of external vendors on the cost of early-stage clinical trials while the company maintains internal control over production.
Main competitors
Net earnings per share growth forecast for next year Haleon plc|Expected net earnings per share growth next year kenvue.com KVUE|Net earnings per share growth forecast for next year Verona Pharma (VRNA)|MENS (Jyong Biotech Limited) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Ligand Pharma LGND|Earnings growth forecast for next year Amneal Corp AMRX|Perrigo Company PLC - Earnings growth forecast for next year|ALVO: Net earnings per share growth forecast for next year|liquidia.com (LQDA) - Net earnings per share growth forecast for next year|GLPG (Galapagos) - Net earnings per share growth forecast for next year|Expected earnings per share growth for next year ANIP|Projected earnings per share growth rate for next year MNKD (Afrezza)|Net earnings per share growth forecast for next year Pacira BioSciences (PCRX)|SPRY: Net earnings per share change forecast for next year|Theravance Biopharma, Inc. - Expected earnings per share growth for next year|Projected earnings per share increase next year AQST (Aquestive Therapeutics, Inc.)|SCPH - Net earnings per share growth forecast for next year|Consensus forecast of earnings per share growth for next year tectonictx.com TECX|TNXP: Earnings growth forecast for next year|Projected earnings per share growth rate for next year SXTC|Expected earnings per share growth for next year EPRX|BioHarvest (BHST) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year EXOZ|Earnings growth forecast for next year Oramed (ORMP)|Entera Bio Ltd. - Expected earnings per share growth for next year|ipatherapeutics.com (HYFT) - Expected net earnings per share growth next year|ABVC - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year CPIX|QNTM: Earnings growth forecast for next year|FGEN - Consensus forecast of earnings per share growth for next year|TELO (Telomir Pharmaceuticals Corp) - Earnings growth forecast for next year|RANI (Rani Therapeutics) - Projected earnings per share increase next year|Net earnings per share growth forecast for next year Synergy CHC Corp. (SNYR)|RLYB (Rallybio) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year lexariabioscience.com LEXX|Earnings growth forecast for next year Pulmatrix Corporation PULM|PTHL - Net earnings per share growth forecast for next year|Consensus forecast of earnings per share growth for next year Aptorum Group Ltd APM|LYRA (Lyra Therapeutics) - Expected earnings per share growth for next year|IBO - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year TNF Pharmaceuticals, Inc.|Expected earnings per share growth for next year cbdMD, Inc. (YCBD)|Net earnings per share growth forecast for next year PainReform Limited (PRFX)|Expected earnings per share growth for next year Altamira Therapeutics Ltd CYTO|Earnings growth forecast for next year LIPO (lipella.com)|Expected earnings per share trend next year OPTN|PIRS - Net earnings per share growth forecast for next year|Procaps Group Corp (PROC) - Expected earnings per share growth for next year|Petros (PTPI) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year QLI (Qilian International)|Expected earnings per share growth for next year SLRN|TFF Pharmaceuticals, Inc. - Net earnings per share change forecast for next year
